AOD9604 vs GLP-1s for weight loss: what the research actually shows

A recent TikTok video by a nurse practitioner poses a question that is generating buzz in wellness circles: “What is better for weight loss—GLP-1s or AOD 9604?” The clip, aimed at a med-spa audience, implies a head-to-head comparison and suggests that AOD9604 might be a viable alternative to prescription GLP-1 receptor agonists. But what does the research actually say? Let’s separate the science from the soundbite.

What the clip claims

The video frames AOD9604 as a potential rival to GLP-1 medications like semaglutide or tirzepatide, hinting that it could offer similar weight-loss benefits with fewer side effects or a different mechanism. The creator, speaking from a clinical perspective, implies that patients are asking which option is “better,” and the clip suggests AOD9604 deserves serious consideration. However, the 15-second format leaves out crucial context about study quality, regulatory status, and clinical outcomes.

What the research actually covers

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) are FDA-approved for weight management in appropriate candidates. Their efficacy is backed by large, randomized controlled trials showing significant weight loss—often 10–20% of body weight—along with improvements in cardiometabolic markers. These drugs work by mimicking incretin hormones, reducing appetite, and slowing gastric emptying.

AOD9604, on the other hand, is a modified fragment of human growth hormone (hGH) (amino acids 177–191). It was investigated in the early 2000s as a lipolytic agent, with the theory that it could stimulate fat breakdown without the growth-promoting effects of full hGH. Early animal studies and small human trials suggested modest fat loss, but the research pipeline stalled. A Phase II trial for obesity was discontinued, and no large-scale, peer-reviewed human studies have confirmed its efficacy or long-term safety. As of now, AOD9604 is not approved by any major regulatory body for weight loss.

Limits and missing context

The clip’s comparison is misleading because it equates a well-studied pharmaceutical class with an experimental peptide that lacks robust clinical validation. A 15-second video cannot convey the nuances of study design, dosing, or adverse event profiles. For instance, GLP-1s have known gastrointestinal side effects, but they also have extensive safety data. AOD9604’s safety profile is largely unknown, with theoretical concerns about immune responses or off-target effects. Moreover, the clip does not mention that AOD9604 is typically sold as a research chemical, not a prescription medication, and its use in humans is not supported by clinical guidelines.

How this maps to research compounds

For researchers exploring peptide pathways, AOD9604 (Fragment 176-191) is available in our catalog as a research-use-only compound. It is often studied alongside other metabolic peptides like GHRP-6, Ipamorelin, and CJC-1295, which influence growth hormone secretion and lipid metabolism. However, none of these have the clinical evidence base of GLP-1 receptor agonists. If a clip mentions GLP-1s, it is important to note that semaglutide and tirzepatide are not peptides sold for research; they are regulated pharmaceuticals. Our catalog does not list them, and we do not suggest substituting research peptides for approved therapies.

Research-use caveat

All peptides in our catalog are intended for laboratory research and in vitro studies only—not for human or animal use. The information presented here is for educational purposes and does not constitute medical advice. Always consult primary literature and follow institutional guidelines when designing experiments.

Open the full video fact-check page (transcript, takeaways, embedded clip).